We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 18, 2021

Early Treatment Effects of Fluvoxamine on COVID-19

The Lancet Global Health

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Global Health
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Lancet Glob Health 2021 Oct 27;[EPub Ahead of Print], G Reis, EA Dos Santos Moreira-Silva, DCM Silva, L Thabane, AC Milagres, TS Ferreira, CVQ Dos Santos, VH de Souza Campos, AMR Nogueira, APFG de Almeida, ED Callegari, AD de Figueiredo Neto, LCM Savassi, MIC Simplicio, LB Ribeiro, R Oliveira, O Harari, JI Forrest, H Ruton, S Sprague, P McKay, AV Glushchenko, CR Rayner, EJ Lenze, AM Reiersen, GH Guyatt, EJ Mills

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading